Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial
Purpose: A primary analysis of the ongoing NIVAHL trial demonstrated unexpectedly high interim complete response rates to nivolumab-based first-line treatment in early-stage unfavorable Hodgkin lymphoma. However, biomarkers such as metabolic tumor volume (MTV) or total lesion glycolysis (TLG) and th...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2021
|
| In: |
Clinical cancer research
Year: 2021, Volume: 27, Issue: 2, Pages: 402-407 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-20-3303 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-20-3303 Verlag, lizenzpflichtig, Volltext: https://clincancerres.aacrjournals.org/content/27/2/402 |
| Author Notes: | Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, Helen Goergen, Horst Müller, Christian Baues, Ulrich Keller, Julia Meissner, Karolin Trautmann-Grill, Andrea Kerkhoff, Michael Fuchs, Stephanie Sasse, Bastian von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert, Carsten Kobe, and Paul J. Bröckelmann |
Search Result 1
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
Article (Journal)
Online Resource